Adherence intervention for HIV-infected patients receiving antiretroviral treatment: Implementation and initial assessment;Consultation d'observance pour des malades infectés par le VIH et traités par antirétroviraux dans un service de maladies infectieuses et tropicales: Mise en place et première évaluation

Presse Medicale

Volumn 35, Issue 9 I, 2006, Pages 1241-1248

  Berki Benhaddad, Zohra ^a   Ecobichon, Jean Luc ^a   Mentré, France ^a   Capillon, Annie ^a   Certain, Agnès ^a   Secondi, Catherine ^a   Gervais, Anne ^a   Longuet, Pascale ^a   Vildé, Jean Louis ^a   Leport, Catherine ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; BEHAVIOR; CD4 LYMPHOCYTE COUNT; COUNSELING; CULTURAL ANTHROPOLOGY; DEMOGRAPHY; EDUCATION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NURSE; PHARMACIST; PSYCHOLOGIST; SOCIAL STATUS; TIME SERIES ANALYSIS; TREATMENT FAILURE; VIRUS LOAD;

EID: 33748702139     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74796-0     Document Type: Article

References (36)

1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133: 21-30.
2. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000; 30: 5171-6.
3. Delfraissy JF. Prise en charge thérapeutique des personnes atteintes par le VIH. Recommandations du groupe d'experts. Mise à jour 2002 et 2004. Médecine sciences ed. Paris: Flammarion; 2002, 2004.
4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced humain immunodeficiency virus infection; HIV Outpatient Study Investigators. N Engl J Med. 1998; 338: 853-60.
5. Le Moing V, Chêne G, Carrieri P, Besnier JM, Masquelier B, Salamon R et al. Clinical, biologic and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acq Immune Def Synd. 2001; 27: 372-6.
6. Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003; 362: 679-86.
7. Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet F et al. The dynamic of adherence to highly active antiretroviral therapy: results from the french national APROCO Cohort. J Acquir Immune Defic Syndr. 2001; 28: 232-9.
8. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti J. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002; 54: 1481-96.
9. Moss AR, Hahn JA, Perry S, Charlebois ED, Guzman D, Clark RA et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: A Prospective Study. Clin Infect Dis. 2004; 39: 1190-8.
10. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001; 15: 1181-3.
11. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004; 53: 696-9.
12. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003; 17: 169-77.
13. Berki-Benhaddad Z, Certain A, Leport C, Farinotti R, Vildé JL. Impact psychologique, approche descriptive du vécu quotidien et de l'information sur le bon usage des traitements médicamenteux des personnes infectées par le VIH. Médecine de l'Homme 2000; 248: 26-34.
14. Moatti JP, Spire B, Duran S. A review of sociobehavioural studies on adherence to antiretroviral treatments: beyond biomedical models? Rev Epidemiol Sante Publique. 2000; 48: 182-97.
15. Pradier C, Bentz L, Spire B, Tourette-Turgis C, Morin M, Souville M et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials. 2003; 4: 121-31.
16. Carrieri P, Raffi F, Lewden C, Sobel A, Michelet C, Cailleton V et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3 year follow-up study. Antiviral Therapy. 2003; 8: 585-94.
17. Daar ES, Cohen C, Remien R, Sherer R, Smith K. Improving adherence to antiretroviral therapy. AIDS Read. 2003; 13: 81-2, 85-6, 88-90.
18. Le Moing V, Chêne G, Carrieri P, Alioum A, Brun-Vézinet F, Piroth L et al. Predictors of virological rebound in HIV1-infected patients initiating a protease inhibitor-containing regimen. AIDS. 2002; 16: 21-9.
19. Tuldra A, Fumaz CR, Ferrer MJ, Bayés R, Arno A, Balagué M et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000; 25: 221-8.
20. Starace F, Ammassari A, Trotta MP, Murri R, De Longis P, Izzo C et al. Depression is risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31 (Suppl 3): 5136-9.
21. Leclerc S, Brunschwig O, Berki-Benhaddad Z, Soyris D, Grataud C, Breton Q et al. Traitement antirétroviral chez des patients schizophrènes infectés par le VIH. Presse Med. 2005; 34: 431-7.
22. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS. 2000; 14: 151-5.
23. Ammassari A, Trotta MP, Murri R, Castelli F, Narciso P, Noto P et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002; 31 (Suppl 3): S123-7.
24. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999; 13: 1763-9.
25. Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001; 2: 38-45.
26. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.C.O.N.A. Study Group. Italien Cohort of Antiretroviral- Naïve Patients. AIDS 2000; 14: 499-507.
27. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS. 2001; 15: 1517-26.
28. Stone VE, Hogan JW, Schuman P, Rompalo AM, Howard AA, Korkontzelou C et al. Antiretroviral regimen complexity, self-reported adherence, and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr. 2001; 28: 124-31.
29. Kûbler-Ross E. Les derniers instants de la vie. Eabor et Fides éd., 1976.
30. Gfeller R, Assal JR Le vécu du malade diabétique. Folio Psychopratica Hoffmann-La Roche et Cie, Suisse, 1979.
31. Freud S. Deuil et mélancolie. Œuvres complètes, Tome 13. Presse Universitaire de France, Paris, 1988.
32. Lacroix A, Kaufmann C, Gfeller R, Assal JP. Un entretien de groupe avec des patients centré sur la dimension subjective de leur maladie, le diabète sucré. Intérêt et difficultés de cette approche pour les patients et les soignants. Psychol Med. 1987; 19: 2555-60
33. Pierret J. Une approche dynamique du traitement chez des personnes infectées par le VIH: la notion d'intégration. In: L'observance aux traitements contre le VIH/sida. Paris: ANRS, Sciences sociales et sida. 2001: 67-78.
34. Tuldra A, Wu AW. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2002; 31 (Suppl 3): 5154-7.
35. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002; 29 (Suppl 1): 52-10.
36. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care. 2002; 14: 309-18.